Psychiatric genetics - The new era: Genetic research and some clinical implications

British Medical Bulletin

Volumn 73-74, Issue , 2005, Pages 107-122

  Prathikanti, Sridhar ^a   Weinberger, Daniel R ^a,b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE MAPPING; GENETIC MANIPULATION; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HERITABILITY; HUMAN; LINKAGE ANALYSIS; MENTAL DISEASE; MICROSATELLITE MARKER; NEUROBIOLOGY; NEUROIMAGING; NEUROPSYCHIATRY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

CHROMOSOMES, HUMAN; CYTOCHROME P-450 ENZYME SYSTEM; DNA; ETHNIC GROUPS; FAMILY HEALTH; GENOTYPE; HAPLOTYPES; HUMANS; LINKAGE (GENETICS); MENTAL DISORDERS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; VARIATION (GENETICS);

EID: 29644442521     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldh055     Document Type: Review

References (44)

1. http://www.fda.gov/bbs/topics/news/2004/new01149.html
2. Harrison PJ, Weinberger DR (2005) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry, 10, 40-68.
3. Coty C. Genomics & Proteomics March 2003 http://www.keepmedia.com/ pubs/GenomicsProteomics/2003/03/01/117001.
4. Caspi A, Sugden K, Moffitt TE et al. (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science, 301, 386-389.
5. Risch N (1990) Linkage strategies for genetically complex traits. I. Multilocus models. Am J Hum Genet, 46, 222-228.
6. Prathikanti S, Francis FJ (2001) Genome scans for susceptibility genes in bipolar affective disorder. Ann Med, 33, 257-262.
7. Risch N, Merikangas K (1996) The future of genetic studies of complex human diseases. Science, 273, 1516-1517.
8. Genomics & Proteomics, September 2004. http://www.keepmedia.com/acct/ QuickRegSubmit.do;jsessionid=anwSmxxkkUq7
9. http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-04-003.html
10. Kremen WS, Faraone SV, Seidman LJ, Pepple JR, Tsuang MT (1994) Neuropsychological risk indicators for schizophrenia: a preliminary study of female relatives of schizophrenic and bipolar probands. Psychiatr Res, 79, 227-240.
11. Egan MF, Leboyer M, Weinberger DR (2004) Intermediate phenotypes in genetic studies of schizophrenia. In: Hirsch SR, Weinberger DR (eds) Schizophrenia. London: Blackwell.
12. Callicott JH, Egan MF, Mattay VS et al. (2003) Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am J Psychiatry, 160, 709-719.
13. Egan MF, Goldberg TE, Kolachana BS et al. (2001) Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA, 98, 6917-6922.
14. Egan MF, Straub RE, Goldberg TE et al. (2004) Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci USA, 101, 12604-12609.
15. Egan M, Goldberg T, Gscheidle T, Bigelow L, Hyde T, Weinberger D (2001) Relative risk for cognitive impairments in siblings of patients with schizophrenia. Biol Psychiatry, 50, 98-107.
16. McGue M, Gottesman II (1989) A single dominant gene still cannot account for the transmission of schizophrenia. Arch Gen Psychiatry, 46, 478-480.
17. Bookheimer SY, Strojwas MH, Cohen MS et al. (2000) Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med, 343, 450-456.
18. Egan MF, Kojima M, Callicott JH et al. (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell, 112, 257-269.
19. Hariri AR, Mattay VS, Tessitore A et al. (2002) Serotonin transporter genetic variation and the response of the human amygdala. Science, 297, 400-403.
20. Bertolino A, Caforio G, Blasi G et al. (2004) Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry, 161, 1798-1805.
21. Weickert TW, Goldberg TE, Mishara A et al. (2001) COMT Val108/158Met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry, 56, 677-682.
22. Inada T, Nakamura A, Iijima Y (2003) Relationship between catechol-O-methyltransferase polymorphism and treatment-resistant schizophrenia. Am J Med Genet, 120B, 35-39.
23. Anttila S, Illi A, Kampman O, Mattila KM, Lehtimaki T, Leinonen E (2004) Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics. Pharmacogenetics, 14, 303-307.
24. Wei J, Hemmings GP (2000) The NOTCH4 locus is associated with susceptibility to schizophrenia. Nat Genet, 25, 376-377.
25. Yu YW-Y, Tsai S-J, Chen T-J, Lin C-H, Hong C-J (2002) Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry, 7, 1115-1119.
26. Bloche MG (2004) Race-based therapeutics. N Engl J Med, 351, 2035-2037.
27. Taylor AL, Ziesche S, Yancy C et al. (2004) Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med, 351, 2049-2057.
28. Dettling M, Schaub RT, Mueller-Oerlinghausen B, Roots I, Cascorbi I (2001) Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry. Pharmacogenetics, 11, 135-141.
29. Frueh FW, Gurwitz D (2004) From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics, 5, 571-579.
30. O'Kane DJ, Weinshilboum RM, Moyer TP (2003) Pharmacogenomics and reducing the frequency of adverse drug events. Pharmacogenomics, 4, 1-4.
31. Matthew Herper. The World's Best-Selling Drugs. Forbes Magazine. March 16, 2004.
32. Johnson JA, Bootman JL (1995) Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med, 155, 1949-1956.
33. CYP2C19 Genotyping worth it for H. pylori eradication in the US. Pharmacoeconomics Outcomes News Weekly 2003, 443, 7.
34. Fishbain DA, Fishbain D, Lewis J et al. (2004) Genetic testing for enzymes of drug metabolism: does it have clinical utility for pain medicine at the present time? A structured review. Pain Med, 5, 81-93.
35. Wedlund PJ, de Leon J, Davis G. Pharmacogenetic testing in the clinic and cost comparisons. In: Proceedings of the VII Stowe Symposium, July 1999, Stoke Rochford, UK: UK Metabolism Group.
36. Scordo MG, Spina E (2002) Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics, 3, 201-218.
37. Kirchheiner J, Sasse J, Meineke I, Roots I, Brockmoller J (2003) Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity. Pharmacogenetics, 13, 721-728.
38. Daly AK, Cholerton S, Gregory W, Idle JR (1993) Metabolic polymorphisms. Pharmacol Ther, 57, 129-160.
39. Furman KD, Grimm DR, Mueller T et al. (2004) Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics. Pharmacogenetics, 14, 279-284.
40. de Leon J, Susce MT, Pan RM et al. (2005) The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry, 66, 15-27.
41. van der Weide J, Steijns LS, van Weelden MJ (2003) The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics, 13, 169-172.
42. Green EK, Raybould R, Macgregor S et al. (2005) Operation of the schizophrenia susceptibility gene, neuregulin 1, across traditional diagnostic boundaries to increase risk for bipolar disorder. Arch Gen Psychiatry, 62, 642-648.
43. Raybould R, Green EK, Macgregor S et al. (2005) Bipolar disorder and polymorphisms in the dysbindin gene (DTNBP1). Biol Psychiatry, 57, 696-701.
44. Maier W, Hofgen B, Zobel A et al. (2005) Genetic models of schizophrenia and bipolar disorder: overlapping inheritance or discrete genotypes? Eur Arch Psychiatry Clin Neurosci, 255, 159-166.